Hot Jobs

Looking for Career in Pharmacovigilance/ Clinical Research. Enter details here.

Wednesday, 21 May 2014

Job opening in Zydus Cadila Ahmedabad as Research Associate - Pharmacovigilance for 2 years exp. "D"

 
Careers
Zydus Cadila is an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products. The group's operations range from API to formulations, animal health products and cosmeceuticals. Headquartered in the city of AhmedAPPLYabad in India, the group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.

In its mission to create healthier communities globally, Zydus Cadila delivers wide ranging healthcare solutions and value to its customers. With over 13,000 employees worldwide, a world-class research and development centre dedicated to discovery research and eight state-of-the-art manufacturing plants, the group is dedicated to improving people"s lives.
DesignationResearch Associate - Pharmacovigilance
Job Description
  • Clinical Case Processing
  • Quality check reviewer
  • Medical Inquiry Handling
  • PADER review
  • Literature search
Desired Profile
  • Candidate should possess experience of Phamacovigilance
  • Candidate should possess good communication and interpersonal skills.
Experience2 - 4 Years
Industry TypePharma / Biotech / Clinical Research
RoleRegulatory Affairs Manager
Functional AreaMedical, Healthcare, R&D, Pharmaceuticals, Biotechnology
EducationUG - B.Pharma - Pharmacy
PG - M.Pharma - Pharmacy
DOCTORATE - Any Doctorate - Any Specialization, Doctorate Not Required
Compensation:Best in Industry
LocationAhmedabad
Keywordsregulatory affairspharmacovigilancecase processingmedical inquiry
ContactCadila Healthcare Limited 
Job Posted19 May

























Content provided by Zyduscadila, Info Edge India Limited disclaims all warranties against infringement.
Visit Security Guidelines and Terms and conditions for more comprehensive information in this regard

No comments:

Post a Comment

Subscribe to us